Landipirdine

Drug Profile

Landipirdine

Alternative Names: RO-5025181; RO5025181-000; SYN-120

Latest Information Update: 02 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Developer Acorda Therapeutics; Biotie Therapies Corp.
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase II Parkinson's disease
  • No development reported Cognition disorders

Most Recent Events

  • 01 Mar 2017 Phase-II development for Parkinson’s disease-related dementia is ongoing in USA (PO)
  • 01 Mar 2017 No recent reports on development identified - Phase-I for Cognition disorders in USA (PO)
  • 25 Jan 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top